Company NewsIndustry News

Good news! Kati won the "Second Prize" in the "Entrepreneurship Jiangsu" competition

Date:2020.12.01   Views:421


      Nanjing Kati Medical Technology Co., Ltd. is operated by the Provincial Department of Science and Technology, the Provincial Talent Office, the Provincial Party Committee Propaganda Department, the Provincial Party Committee Cyberspace Affairs Office, the Provincial Development and Reform Commission, the Provincial Department of Education, the Provincial Department of Finance, the Provincial Department of Human Resources and Social Security, and the Provincial Committee of the Communist Youth League. In the 8th "Entrepreneurship Jiangsu" Science and Technology Entrepreneurship Competition organized jointly by the Provincial Federation of Industry and Commerce and other units, it won the "second prize".

Nanjing Kati Medical Technology Co., Ltd. won the "Second Prize" in the 8th "Entrepreneurship Jiangsu" 

Technology Entrepreneurship Competition.

     This year, more than 20,000 companies participated in the competition, and 47 projects were finally shortlisted in the "Entrepreneurship Jiangsu" Science and Technology Entrepreneurship Competition. These projects involve a new generation of information technology, biology, high-end equipment manufacturing, new materials, new energy and new energy vehicles, energy conservation and environmental protection and other strategic emerging industries. It is divided into three groups: team group, start-up company group and growth company group.

     In the end, Nanjing Katy Medical Technology Co., Ltd. won the second prize of the growth enterprise group in the industry-wide competition after the first place in the Jiangsu pharmaceutical industry.

Frontiers of Medicine: Immunotherapy and

 gene editing make tumor removal no longer a dream

     Dr. Wang Enxiu, the founder of Nanjing Kati Medical Technology Co., Ltd., mentioned that with the great success in hematoma, CAR-T immune cell therapy is not ideal for solid tumors. Therefore, he proposed the concept of big CAR. Kati’s team developed the design structure of the core components of the new generation of CAR-T and proved its effect in clinical practice.

     After three years of development, Nanjing Katy Medicine has also built its own team of elites capable of scientific research and development on a mature R&D and production platform. Kati will continue to work hard to promote the development of immune cell therapy and help more cancer patients regain their health!